Nanobiotix Announces Final Data from Phase 1 Study of JNJ-1900 in Cutaneous Melanoma

Nanobiotix S.A. has released final data from its Phase 1 'Study 1100' for the investigational product JNJ-1900 (NBTXR3), targeting patients with anti-PD-1-resistant advanced primary cutaneous melanoma. The study examines the use of NBTXR3 alongside radiotherapy and immune checkpoint inhibitors like nivolumab or pembrolizumab. The company is assessing the efficacy and safety of this nanotherapeutic approach in conjunction with standard treatments for advanced solid tumors.